Parnassus Investments, an investment management firm that focuses on owning a concentrated portfolio of U.S. large cap stocks ...

In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.

The far-right Patriots for Europe (PfE), currently the third-largest group in the European Parliament, achieved a major ...

US pharma giant Pfizer has criticized the recent inclusion of the company in the list of enterprises that should be denied ...

Pfizer stock still looks cheap ahead of its upcoming Q2 earnings release on Aug. 5. Moreover, investors can make extra income ...

For reference, Seeking Alpha's Quant system is driven by powerful computer processing and SA's special 'Quantamental' ...

Jim Cramer threw a curveball on Pfizer’s stock during a recent caller interaction, suggesting a wait-and-see approach ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.50, implying a 14.97% upside from current levels. In a report released yesterday, Bernstein also maintained a Hold rating ...

MEP Ondrej Knotek believes that Europe does not need to lead in the fight against climate change and disputes the 2050 goal ...

Do you know how hard it is to find a stock as bad as Pfizer Inc (NYSE:PFE) like in the last couple of years? I managed the ...

Biotech giant Bristol-Myers Squibb Company (BMY) is scheduled to report second-quarter 2025 results on July 31, before market ...

Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...